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Paradigms and perspectives
AllergoOncology: IgE- and IgG4-mediated immune
mechanisms linking allergy with cancer and their
translational implications
Erika Jensen-Jarolim, MD,a,b Michelle C. Turner, PhD,c,d,e,f and Sophia N. Karagiannis, PhDg,h Vienna, Austria; Barcelona
and Madrid, Spain; Ottawa, Ontario, Canada; and London, United Kingdom
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Since the detection of specific IgE in allergy, its potential role
in cancer has been investigated and prompted the definition of the
field of AllergoOncology.1 Most recent developments are
collected in a position paper by the EuropeanAcademy of Allergy
and Clinical Immunology.2
IgE AND CANCER
IgE is an antibody with properties distinct from those of other
isotypes, specifically in terms of its affinity for its cognate Fc
receptor FcεRI. FcεRI-IgE immune complex formation can
activate potent effector cells normally associated with acute and
chronic allergic responses. IgE effector cells, such as eosinophils,
mast cells, and macrophages, are also known to infiltrate tumors;
tumor-associated tissue eosinophilia (TATE) or tumor-associated
macrophages (TAMs, which can constitute up to 50% of a tumor
mass and can be alternatively activated, M2) are characteristics of
tumor inflammation. While intratumoral or stromal mast cells
have been correlated with tumor promotion, signs of mast cell
degranulation, normally associated with IgE–immune complex
formation, have been correlated with a more favorable prognosis.
Mast cells are a prominent source of the proinflammatory
cytokine TNF-a, which is known to promote antitumor immunity.
Other released mediators turn on acute (histamine) or chronic
(eg, slow-reacting substance of anaphylaxis and cytokines)
inflammation and promote amplification of innate effector
mechanisms. These cells can harbor cytotoxic and phagocytic
potential, which could be directed against tumors.
The potential efficacy of IgE antibodies engineered to
recognize tumor antigens is exemplified in vitro by using
cell-based assays, suggesting that IgE directed against
tumor antigens engenders antibody-dependent cell-mediated
cytotoxicity (ADCC) by human monocytes, whereas, through
its interaction with FcgRs, IgG1 of the same antigen specificity
can instruct the same cells to trigger antibody-dependent
cell-mediated phagocytosis (ADCP). IgE anti-cancer antibodies
engage subsets of FcεRI-expressing effector cells to mediate
ADCC against tumors without the inhibitory Fc receptor
signals known to limit IgG effector functions in the tumor
microenvironment. IgE is cross-linked by densely packed tumor
antigens but not by soluble monovalent antigens, forming
tumor-associated molecular patterns (TAMPs) on a cancer cell
surface and therefore triggering effector cell activation at sites
where antitumor immunity is needed (Fig 1). Therefore it is
tempting to speculate that IgE antibodies directed against tumor
antigens can propagate alternative or complementary antitumor
functions to those of clinically available IgG mAbs specific for
tumor antigens, such as epidermal growth factor receptor
(EGFR) and human epidermal growth factor receptor 2
(HER2). Prompted by promising preclinical studies in numerous
in vivo models of cancer and in nonhuman primates, the first
clinical trial of an antitumor IgE antibody in patients with cancer
is ongoing (NCT02546921).
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FROM TH2 IMMUNE RESPONSES IN PATIENTS
WITH ALLERGY AND ATOPY TO CANCER
EPIDEMIOLOGY
Allergy is characterized by TH2-dominant immune responses,
featuring IL-4, IL-13, and thymic stromal lymphopoietin
upregulation. Because these mediators can be observed in
cancer tissues, strategies to activate these responses could in
principle promote isotype switching to antitumor IgE and also
IgE/FcεRI-associated cross-presentation by dendritic cells,
resulting in activation of CD41T cells but also of CD81 cytotoxic
T lymphocytes. Therefore although TH1 responses and a strong
branch of CD81 cytotoxic T lymphocytes are generally desired
in oncology, activation of classical TH2 cells has also been
associated with improved survival. On the other hand, TATE
and TAMs, especially those alternatively activated M2
populations, might be signs of a TH2-biased immune response
unable to restrict cancer growth. Evidence of an alternative TH2
inflammatory milieu featuring enhanced IL-10 rather than IL-4
in patients with many cancers, includingmelanoma, can influence
class-switching away from IgE and perhaps favor expression of
isotypes with more restricted effector functions, such as IgG4 or
IgA.
Therefore the question remains whether allergies in general can
protect against cancer. Epidemiologic meta-analyses suggest a
strong inverse association between allergy and atopy and risk of
glioma, pancreatic cancer, and childhood leukemia, although
there are limitations in previous studies related to measures of
allergy history and latency period.3 Inverse associations of
prediagnostic IgE and cancer risk have also been reported overall,
as well as for glioma specifically,4,5 but fewer associations have
been reported at other cancer sites.2 Prospective studies in large
cohorts are required to further understand the potential role of
IgE and other immunologic parameters in cancer risk and poten-
tial underlying biological mechanisms to be able to better harness
‘‘classical’’ TH2 immune responses and IgE against cancer.
IMMUNE TOLERANCE: GOOD OR BAD?
Immunotherapy strategies in oncology are hampered by an
overwhelming immunosuppressive microenvironment in and
FIG 1. Antibody isotypes direct effector functions of innate immune cells infiltrating tumors. Left,
Intratumoral IgG4 supported by IL-10 and vascular endothelial growth factor (VEGF) produced by cancer
and immune cells. IgG4 occurs as intact IgG4 antibody (a); can undergo Fab arm exchange (FAE), resulting
in bispecific or half antibodies (b); or can interfere with IgG1 Fc-mediated antitumor functions (c). IgG4might
be unable to cross-link FcgRs on effector cells and engender antitumor functions. Right, Tumor
antigen-specific IgE is shuttled through FcεRI1 effector cells into tumors. Overexpressed tumor antigens
packed in lipid rafts assemble tumor-associated molecular patterns (TAMPs), leading to effective
cross-linking of effector cell-bound IgE, followed by antibody-dependent cellular cytotoxicity (ADCC) and
antibody-dependent cellular phagocytosis (ADCP) of malignant cells (d); soluble monovalent tumor
antigens do not lead to effector cell activation (e). Ag, Antigen; CDC, complement dependent cytotoxicity.
J ALLERGY CLIN IMMUNOL
VOLUME 140, NUMBER 4
JENSEN-JAROLIM, TURNER, AND KARAGIANNIS 983
around tumors. Tumor cells and infiltrating immune cells, such as
regulatory T cells and likely regulatory B cells,6 can secrete
cytokines, such as TGF-b and IL-10, which support immune
tolerance7 and moderate immune surveillance, hindering any
antitumor activities of effector cells. Checkpoint inhibitors
targeting programmed cell death protein 1 (PD-1) or cytotoxic
T lymphocyte–associated antigen 4 (CTLA-4) to unleash the
cytotoxic potential of a patient’s T-cell immunity are major
breakthroughs in clinical oncology, even at the cost of severe
systemic autoimmunity.
In contrast, allergen immunotherapy attempts to re-establish
immune tolerance to the allergen. A hallmark of allergen
immunotherapy is IgG4, which is supported by IL-10–producing
cells, such as regulatory Tand regulatory B cells. IgG4 antibodies
can block allergic responses through various mechanisms, such as
through interacting with the inhibitory FcgRIIb on B cells to
block IgE synthesis.8 IgG4 is also a special antibody isotype
devoid of complement activation properties and with impaired
effector functions. These characteristics might be due to hinge
region sequences that render IgG4 prone to Fab arm exchange
and formation of naturally bispecific antibodies less able to be
cross-linked by an allergen9 and therefore resistant to
allergen-associated molecular patterns (AAMPs) (Fig 1).10
Furthermore, IgG4 might repolarize M2a macrophages to the
immunosuppressive phenotype M2b, which could be responsible
for increased IL-10 secretion.11 Strikingly, IgG4 is expressed in
tissues from patients with malignancies such as melanoma, in
whom it can impair antitumor immunity and correlates with
shorter survival and disease progression.12 There is also
increasing evidence to support positive correlations between
IgG4-related diseases, such as sclerosing cholangitis associated
with autoimmune pancreatitis, with enhanced cancer risk,13
including more recent long-term follow-up investigations.14
However, the antigen specificities of IgG4 antibodies
are unclear.15 Notably, higher levels of IgE and IgG4
recognizing the cancer antigens EGFR and HER2, but not
carcinoembryonic antigen, were detected in the sera of
patients with cancer compared with allergic patients.16 Therefore
the tumor microenvironment could favor class-switching to
IgG4
17 within a ‘‘modified TH2 response’’ in a process that
features high similarities to those reported in patients with cat
allergy.18 Elucidating the conditions promoting IgG4 isotype
switching still requires the design of immunologically relevant
animal models other than rodents, potentially monkeys or
canines.2
Hence the opposite from allergen immunotherapy might be
required in cancer treatment, ie, reduction of ‘‘alternative’’
TH2 isotypes, such as IgG4, in situ and simultaneous
promotion of immune activatory IgE isotypes against cancer
antigens. It might be envisaged that cancer immunotherapy
strategies could aim at shifting existing IgG4 responses to
IgE through sequential isotype switching, perhaps with the
aid of adjuvants.
CONCLUSION
Harnessing components of the ‘‘classical’’ TH2 humoral
immunity against tumors might offer novel oncological treatment
avenues. Thus AllergoOncology might provide strategies that
complement existing and emerging immuno-oncology therapies.
We thank Judit Fazekas for assistance with illustrations.
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